BALTIMORE–(BUSINESS WIRE)–Cerecor Inc. (CERC), a
clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and
psychiatric disorders, today announced the publication of
preclinical data suggesting antidepressant activity of CERC-301.
The paper, titled ‘Preclinical pharmacology and
pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-
D-aspartate receptor antagonist’, was published in the
December issue of the Journal of Pharmacology Research &
Perspectives. This publication reports results of CERC-301 in
an acute preclinical depression model known as the forced swim
test, a common model of antidepressant efficacy. In test
animals, CERC-301 showed antidepressant activity at doses
that had minimal side effects.